Alicia Lau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alicia Lau has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Ana Jaklenec
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
5 shared publications - Robert Langer
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
5 shared publications - Shahad K. Alsaiari
David H. Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology Cambridge Massachusetts USA
4 shared publications - Linzixuan Zhang
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA
3 shared publications Timothy A. Forster
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
3 shared publicationsXin Yang
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
3 shared publications
Latest Publications
- Open Access
- 5 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (23) , eaea5433
Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine
Enteric pathogens are a major contributor to the global disease burden, necessitating vaccines capable of inducing robust gastrointestinal mucosal immunity. Achieving this response is especially challenging with inactivated or subunit vaccines, which lack the ability of live-attenuated formulations to mimic the natural infection process needed to induce strong intestinal mucosal immunity. Specifically, the inactivated polio vaccine (IPV), administered parenterally, elicits strong systemic immunity but fails to induce the mucosal IgA responses required to fully block poliovirus transmission, a critical step toward complete eradication. To address this limitation, we developed a clinically translatable and scalable nanoparticle-based intestinal mucosal adjuvant by encapsulating Am80, a small hydrophobic molecule known to promote intestinal mucosal immunity, within nanoparticles (NPs) designed for lymph node delivery, without requiring antigen modification, encapsulation, or adsorption. Encapsulation in NPs eliminated the need for the use of organic solvents, reduced toxicity, and prevented degradation, while lipid nanoparticles (Am80-LNPs) were engineered for sustained release over 3 to 5 days with high encapsulation efficiency (78 ± 9%). Cy5-labeled Am80-LNPs localized to draining lymph nodes within 6 hours and were retained for up to 72 hours. Coadministration of Am80-LNPs with the licensed IPV-2 in a Wistar rat model significantly boosted IPV-2–specific fecal IgA by 20-fold compared to IPV-2 alone and threefold over free Am80. These findings demonstrate that Am80-LNPs significantly enhance IPV-2–specific mucosal immunity in vivo and suggest their potential as a potent mucosal adjuvant against other enteric pathogens.
- 5 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (23) , eaea5433
Open AccessAm80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine
Enteric pathogens are a major contributor to the global disease burden, necessitating vaccines capable of inducing robust gastrointestinal mucosal immunity. Achieving this response is especially challenging with inactivated or subunit vaccines, which lack the ability of live-attenuated formulations to mimic the natural infection process needed to induce strong intestinal mucosal immunity. Specifically, the inactivated polio vaccine (IPV), administered parenterally, elicits strong systemic immunity but fails to induce the mucosal IgA responses required to fully block poliovirus transmission, a critical step toward complete eradication. To address this limitation, we developed a clinically translatable and scalable nanoparticle-based intestinal mucosal adjuvant by encapsulating Am80, a small hydrophobic molecule known to promote intestinal mucosal immunity, within nanoparticles (NPs) designed for lymph node delivery, without requiring antigen modification, encapsulation, or adsorption. Encapsulation in NPs eliminated the need for the use of organic solvents, reduced toxicity, and prevented degradation, while lipid nanoparticles (Am80-LNPs) were engineered for sustained release over 3 to 5 days with high encapsulation efficiency (78 ± 9%). Cy5-labeled Am80-LNPs localized to draining lymph nodes within 6 hours and were retained for up to 72 hours. Coadministration of Am80-LNPs with the licensed IPV-2 in a Wistar rat model significantly boosted IPV-2–specific fecal IgA by 20-fold compared to IPV-2 alone and threefold over free Am80. These findings demonstrate that Am80-LNPs significantly enhance IPV-2–specific mucosal immunity in vivo and suggest their potential as a potent mucosal adjuvant against other enteric pathogens.
- Open Access
- 7 May 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (65) , e75716
Exploring an Alternative to mRNA Vaccine Cold Chain Storage: MRNA‐Lipid Nanoparticle Stability When Dried in a Polymer Matrix
Cold chain storage requirements limit the accessibility of mRNA vaccines and therapeutics more broadly within the developing world. Polymer microneedles are a promising alternative for overcoming challenges associated with cold chain distribution and vaccine storage, and have additional advantages in ease of application. Herein, we reveal the structural transformations and performance of mRNA‐loaded lipid nanoparticles (LNPs) during dehydration and rehydration within the polymer framework (PVPVA) employed for microneedle fabrication. Cryogenic transmission electron microscopy and in situ small‐angle x‐ray scattering revealed that the LNPs display partial inverse hexagonal packing of the self‐assembled lipid molecules, which can be recovered upon rehydration with sufficient polymer loading (polymer:mRNA > 320:1). The performance of the recovered LNPs is sensitive to polymer loading, and at low polymer loading (polymer:mRNA 32:1), the LNPs are unstable. LNPs of higher N/P ratios (mole ratio of protonatable amines to mole of phosphate groups from mRNA) were more robust to recovery due to improved mRNA encapsulation efficiency (∼20%–80%) and potentially lower loss of mRNA‐loaded carriers during processing (∼3‐fold lower coalescence signal). Balancing the polymer and mRNA loading yielded a 100‐fold increase in transfection for the optimized 5.4 N/P ratio Lipid‐5 system.
- 7 May 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (65) , e75716
Open AccessExploring an Alternative to mRNA Vaccine Cold Chain Storage: MRNA‐Lipid Nanoparticle Stability When Dried in a Polymer Matrix
Cold chain storage requirements limit the accessibility of mRNA vaccines and therapeutics more broadly within the developing world. Polymer microneedles are a promising alternative for overcoming challenges associated with cold chain distribution and vaccine storage, and have additional advantages in ease of application. Herein, we reveal the structural transformations and performance of mRNA‐loaded lipid nanoparticles (LNPs) during dehydration and rehydration within the polymer framework (PVPVA) employed for microneedle fabrication. Cryogenic transmission electron microscopy and in situ small‐angle x‐ray scattering revealed that the LNPs display partial inverse hexagonal packing of the self‐assembled lipid molecules, which can be recovered upon rehydration with sufficient polymer loading (polymer:mRNA > 320:1). The performance of the recovered LNPs is sensitive to polymer loading, and at low polymer loading (polymer:mRNA 32:1), the LNPs are unstable. LNPs of higher N/P ratios (mole ratio of protonatable amines to mole of phosphate groups from mRNA) were more robust to recovery due to improved mRNA encapsulation efficiency (∼20%–80%) and potentially lower loss of mRNA‐loaded carriers during processing (∼3‐fold lower coalescence signal). Balancing the polymer and mRNA loading yielded a 100‐fold increase in transfection for the optimized 5.4 N/P ratio Lipid‐5 system.
- Top Cited PapersOpen Access
- 24 February 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (5) , 794-803
On-patient medical record and mRNA therapeutics using intradermal microneedles
Medical interventions often require timed series of doses, thus necessitating accurate medical record-keeping. In many global settings, these records are unreliable or unavailable at the point of care, leading to less effective treatments or disease prevention. Here we present an invisible-to-the-naked-eye on-patient medical record-keeping technology that accurately stores medical information in the patient skin as part of microneedles that are used for intradermal therapeutics. We optimize the microneedle design for both a reliable delivery of messenger RNA (mRNA) therapeutics and the near-infrared fluorescent microparticles that encode the on-patient medical record-keeping. Deep learning-based image processing enables encoding and decoding of the information with excellent temporal and spatial robustness. Long-term studies in a swine model demonstrate the safety, efficacy and reliability of this approach for the co-delivery of on-patient medical record-keeping and the mRNA vaccine encoding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This technology could help healthcare workers make informed decisions in circumstances where reliable record-keeping is unavailable, thus contributing to global healthcare equity.
- 24 February 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (5) , 794-803
Top Cited PapersOpen AccessOn-patient medical record and mRNA therapeutics using intradermal microneedles
Medical interventions often require timed series of doses, thus necessitating accurate medical record-keeping. In many global settings, these records are unreliable or unavailable at the point of care, leading to less effective treatments or disease prevention. Here we present an invisible-to-the-naked-eye on-patient medical record-keeping technology that accurately stores medical information in the patient skin as part of microneedles that are used for intradermal therapeutics. We optimize the microneedle design for both a reliable delivery of messenger RNA (mRNA) therapeutics and the near-infrared fluorescent microparticles that encode the on-patient medical record-keeping. Deep learning-based image processing enables encoding and decoding of the information with excellent temporal and spatial robustness. Long-term studies in a swine model demonstrate the safety, efficacy and reliability of this approach for the co-delivery of on-patient medical record-keeping and the mRNA vaccine encoding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This technology could help healthcare workers make informed decisions in circumstances where reliable record-keeping is unavailable, thus contributing to global healthcare equity.
- Open Access
- 6 December 2024
- Published by Springer Nature in Nature Chemical Engineering
- Vol. 2 (1) , 77-89
Degradable poly(β-amino ester) microparticles for cleansing products and food fortification
Microplastic pollution is a pressing global crisis caused by the extensive use of nondegradable microplastic materials in daily activities. One effective approach to mitigate this issue is to replace nondegradable plastics with degradable materials that have properties amendable for targeted applications. Here we present the development of a degradable microparticle (MP) platform based on a poly(β-amino ester) (PAE) that degrades into sugar and amino acid derivatives. This PAE MP platform showed functional replacement of nondegradable microplastics used in cleansing products and food fortification. In cleansing products, PAE MPs effectively enhanced the cleansing efficiency of a representative rinse-off product and showed effective removal of potentially toxic elements, as an alternative of traditional nondegradable microbeads. In food fortification, PAE MPs provided robust protection for multiple essential vitamins and minerals against extensive cooking and storage conditions with rapid nutrient release in a simulated human digestion system. Collectively, these PAE MPs present a potential platform to replace microplastic usage on a global scale in many applications.
- 6 December 2024
- Published by Springer Nature in Nature Chemical Engineering
- Vol. 2 (1) , 77-89
Open AccessDegradable poly(β-amino ester) microparticles for cleansing products and food fortification
Microplastic pollution is a pressing global crisis caused by the extensive use of nondegradable microplastic materials in daily activities. One effective approach to mitigate this issue is to replace nondegradable plastics with degradable materials that have properties amendable for targeted applications. Here we present the development of a degradable microparticle (MP) platform based on a poly(β-amino ester) (PAE) that degrades into sugar and amino acid derivatives. This PAE MP platform showed functional replacement of nondegradable microplastics used in cleansing products and food fortification. In cleansing products, PAE MPs effectively enhanced the cleansing efficiency of a representative rinse-off product and showed effective removal of potentially toxic elements, as an alternative of traditional nondegradable microbeads. In food fortification, PAE MPs provided robust protection for multiple essential vitamins and minerals against extensive cooking and storage conditions with rapid nutrient release in a simulated human digestion system. Collectively, these PAE MPs present a potential platform to replace microplastic usage on a global scale in many applications.
- 16 October 2024
- Published by Springer Nature in Nature Reviews Materials
- Vol. 10 (1) , 44-61
CRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells
- 16 October 2024
- Published by Springer Nature in Nature Reviews Materials
- Vol. 10 (1) , 44-61
CRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells